Advanced Search
LIU Zhishuang, ZHENG Yufen, SUN Hongna, YU Feng. Effect of Ginkgo biloba extract on anticoagulation of 4 new oral anticoagulants[J]. Journal of China Pharmaceutical University, 2020, 51(3): 327-332. DOI: 10.11665/j.issn.1000-5048.20200310
Citation: LIU Zhishuang, ZHENG Yufen, SUN Hongna, YU Feng. Effect of Ginkgo biloba extract on anticoagulation of 4 new oral anticoagulants[J]. Journal of China Pharmaceutical University, 2020, 51(3): 327-332. DOI: 10.11665/j.issn.1000-5048.20200310
shu

Effect of Ginkgo biloba extract on anticoagulation of 4 new oral anticoagulants

Funds: This study was supported by the Basic Research Foundation of China Pharmaceutical University (No. 2632019PY05)
More Information
  • Received Date: February 18, 2020
  • Revised Date: April 29, 2020
    Graphical Abstract
    • Abstract
  • To explore the effect of Ginkgo biloba extract (GBE) on anticoagulation of 4 new oral anticoagulants (NOACs), dabigatran, apixaban, rivaroxaban and edoxaban in vitro, thrombin time (TT), prothrombin time (PT), activated partial thrombin time (APTT) and the activity of coagulation factor Xa (FXa) of rat plasma were measured at different concentrations of NOACs, GBE or NOACs combined with GBE, respectively. The results showed that TT, PT and APTT were prolonged with the increase of NOACs concentration in the range of 0-500 ng/mL; that except for TT of rivaroxaban, other results showed a good linear correlation with NOACs concentration (r2= 0.78-0.98); and that FXa activity decreased with increased concentration of FXa inhibitors (apixaban, rivaroxaban and edoxaban), with a good linear correlation with concentration of FXa inhibitors in the range of 0-250 ng/mL (r2= 0.85-0.94). GBE had no significant effect on TT, PT and APTT (P>0.05) in the concentration range of 0-500 μg/mL, but FXa activity had a positive linear correlation with GBE concentration (r2= 0.840 4). TT was prolonged with increasing GBE concentration when dabigatran was combined with GBE. When the above FXa inhibitors were combined with GBE, TT shortened and FXa activity increased with rising GBE concentration. There were no significant changes in PT and APTT (P>0.05) when NOACs were combined with GBE. The study results suggest that GBE may synergize with the anticoagulant activity of dabigatran and antagonize the anticoagulant activity of FXa inhibitors, possibly due to its role in increasing FXa activity.
    • FullText(HTML)
    • References (19)
  • [1]
    . Eur Heart J， 2018， 39（16）： 1330-1393.
    [2]
    Tran HA， Gibbs H， Merriman E， et al. New guidelines from the Thrombosis and Haemostasis Society of Australia and New Zealand for the diagnosis and management of venous thromboembolism［J］. Med J Aust， 2019， 210（5）： 227-235.
    [3]
    Saar JA， Maack C， European Society of Cardiology. Diagnosis and management of acute pulmonary embolism. ESC guidelines 2014［J］. Herz， 2015， 40（8）： 1048-1054.
    [4]
    Wang GX， Cao FL， Chen J. Progress in researches on the pharmaceutical mechanism and clinical application of Ginkgo Biloba extract on various kinds of diseases［J］. Chin J Integr Med， 2006， 12（3）： 234-239.
    [5]
    Tian JF， Liu Y， Chen KJ. Ginkgo biloba extract in vascular protection： molecular mechanisms and clinical applications［J］. Curr Vasc Pharmacol， 2017， 15（6）： 532-548.
    [6]
    Li JY， Fang J， Zhong FY， et al. Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of dabigatran etexilate， intermediate metabolite and dabigatran in 50 μL rat plasma and its application to pharmacokinetic study［J］. J Chromatogr B Analyt Technol Biomed Life Sci， 2014， 973C： 110-119.
    [7]
    Gai SC， Huang AL， Feng T， et al. LC-MS/MS method for simultaneous determination of rivaroxaban and metformin in rat plasma： application to pharmacokinetic interaction study［J］. Bioanalysis， 2019， 11（24）： 2269-2281.
    [8]
    He K， Luettgen JM， Zhang DL， et al. Preclinical pharmacokinetics and pharmacodynamics of apixaban， a potent and selective factor Xa inhibitor［J］. Eur J Drug Metab Pharmacokinet， 2011， 36（3）： 129-139.
    [9]
    Ude C， Schubert-Zsilavecz M， Wurglics M. Ginkgo biloba extracts： a review of the pharmacokinetics of the active ingredients［J］. Clin Pharmacokinet， 2013， 52（9）： 727-749.
    [10]
    Chen TR， Wei LH， Guan XQ， et al. Biflavones from Ginkgo biloba as inhibitors of human thrombin［J］. Bioorg Chem， 2019， 92： 103199.
    [11]
    Hirsch GE， Viecili PRN， de Almeida AS， et al. Natural products with antiplatelet action［J］. Curr Pharm Des， 2017， 23（8）： 1228-1246.
    [12]
    Diamond BJ， Bailey MR. Ginkgo biloba： indications， mechanisms， and safety［J］. Psychiatr Clin North Am， 2013， 36（1）： 73-83.
    [13]
    Peng YR， Jiang J， Shen H， et al. Pharmacodynamic study of Ginkgo leaf extract on promoting blood circulation［J］. J China Pharm Univ （中国药科大学学报）， 2003， 34（6）： 77-79.
    [14]
    Parasrampuria DA， Truitt KE. Pharmacokinetics and pharmacodynamics of edoxaban， a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor xa［J］. Clin Pharmacokinet， 2016， 55（6）： 641-655.
    [15]
    Gouin-Thibault I， Flaujac C， Delavenne X， et al. Assessment of apixaban plasma levels by laboratory tests： suitability of three anti-Xa assays. A multicentre French GEHT study［J］. Thromb Haemost， 2014， 111（2）： 240-248.
    [16]
    Bookstaver DA， Sparks K， Pybus BS， et al. Comparison of anti-Xa activity in patients receiving apixaban or rivaroxaban［J］. Ann Pharmacother， 2018， 52（3）： 251-256.
    [17]
    Wolzt M， Samama MM， Kapiotis S， et al. Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux［J］. Thromb Haemost， 2011， 105（6）： 1080-1090.
    [18]
    Katsuura Y， Mochizuki T， Tamura M， et al. Species specificity of anticoagulant activity of activated human protein C： involvement of factor V as well as protein S［J］. Thromb Res， 1996， 82（2）： 147-157.
    [19]
    Fernández JA， Heeb MJ， Xu X， et al. Species-specific anticoagulant and mitogenic activities of murine protein S［J］. Haematologica， 2009， 94（12）： 1721-1731.
    • Related Articles

  • Related Articles

    [1]WANG Ziyuan, TAO Hui, XIAO Yingxue, YIN Zhiqi. Network pharmacology-based study of the mechanism of Ginkgo biloba extract (GBE) in the treatment of atherosclerosis by activating PPARγ[J]. Journal of China Pharmaceutical University, 2025, 56(2): 225-235. DOI: 10.11665/j.issn.1000-5048.2024032301
    [2]DONG Xiaoqiang, WEN Chang, XU Jindan, SHI Lexue, HU Yulong, LI Jieming, DONG Chunhong, DING Kan. Research progress on active mechanism and structure feature of polysaccharides from Zizyphus jujube in Rhamnaceae plants[J]. Journal of China Pharmaceutical University, 2024, 55(4): 443-453. DOI: 10.11665/j.issn.1000-5048.2024051301
    [3]LU Zhipeng, XU Qinglong, CHEN Panpan, QIN Yajuan, TANG Lijun, LI Tingyou. Research progress of radioprobes targeting fibroblast activating protein[J]. Journal of China Pharmaceutical University, 2022, 53(6): 651-662. DOI: 10.11665/j.issn.1000-5048.20220603
    [4]MA Rui, TIAN Jinhua, JIANG Jun, JIN Xin. Inhibitory activities of ginsenosides on the activation of NLRP3 inflammasome[J]. Journal of China Pharmaceutical University, 2016, 47(5): 614-618. DOI: 10.11665/j.issn.1000-5048.20160519
    [5]ZHU Kuiniu, WU Zhengfeng, JIANG Cuihua, CAO Lanjie, ZHANG Jian, YIN Zhiqi. Advances on hypoglycemic activity and mechanism of triterpenoids[J]. Journal of China Pharmaceutical University, 2015, 46(6): 764-770. DOI: 10.11665/j.issn.1000-5048.20150622
    [6]SHEN Kai, KOU Junping, YU Boyang. Research advances in the mechanisms of active components in Chinese materia medica against oxidative stress-induced neuronal apoptosis[J]. Journal of China Pharmaceutical University, 2015, 46(5): 532-540. DOI: 10.11665/j.issn.1000-5048.20150503
    [7]WU Keqin. Antitumor activity and mechanism of saikosaponin D combined with oxaliplatin on A549 cells-bearing nude mice[J]. Journal of China Pharmaceutical University, 2015, 46(3): 355-358. DOI: 10.11665/j.issn.1000-5048.20150316
    [8]ZHANG Qian, CHEN Cen, YANG Fengqing, XIA Zhining. Mechanism of agonist-induced platelet activation and research progress of anti-platelet drugs[J]. Journal of China Pharmaceutical University, 2014, 45(6): 632-648. DOI: 10.11665/j.issn.1000-5048.20140604
    [9]SONG Huayuan, ZHOU Danli, HAN Yuan, LIU Wentao. Baicalin attenuates morphine tolerance through suppressing spinal microglia activation in mice[J]. Journal of China Pharmaceutical University, 2014, 45(3): 346-351. DOI: 10.11665/j.issn.1000-5048.20140317
    [10]CHENG Yu-si, DAI De-zai, JI Hui, DAI Yin. Mechanism of endothelin receptor antagonist CPU0213 and calcium antagonist CPU86017 ameliorated rats′ heart failure induced by isoproterenol[J]. Journal of China Pharmaceutical University, 2011, 42(1): 58-63.

  • Cited by

    Periodical cited type(4)

    1. 谢金平，黄淼，朱梦雅，陈怡，邵蓉. 监管科学视角下增材制造(3D打印)药物研发上市关键问题及监管政策研究. 中国食品药品监管. 2025(02): 50-61 .
    2. 王美晴，段小群. 3D打印技术在药物制剂领域的研究进展. 广东化工. 2024(02): 67-68+62 .
    3. 张隽齐，杨柳榴，陈芳. 3D打印技术在膜剂制备中的研究进展. 中国医药工业杂志. 2024(03): 326-334 .
    4. 谭志柱，梁兆铭，邓永健. 3D打印技术在汽车轮胎模具领域的应用案例分析. 机电工程技术. 2024(12): 131-134 .

    Other cited types(4)

Catalog

    Get Citation
    PDF
    XML
    Article views (313) PDF downloads (448) Cited by(8)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：365886

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return